Exhibit 99.1
P R E C I S I O N O N C O L O G Y F O R T H E R A P I E S O F T O M O R R O W Aptose Corporate Presentation NASDAQ: APTO TSX: APS J u l y 2 0 2 2
Disclosure 2 This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or invitation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/or assets of any entity, nor shall it or any part of it be relied upon in connection with or act as any inducement to enter into any contract or commitment or investment decision whatsoever. This presentation contains forward - looking statements , which reflect APTOSE Biosciences Inc.’s (the “Company”) current expectations, estimates and projections regarding future events, including statements relating to our business strategy, our clinical development plans, our ability to obtain the substantial capital we require, our plans to secure strategic partnerships and to build our pipeline, our clinical trials and their projected timeline, the efficacy and toxicity of our product candidates, potential new intellectual property, our plans, objectives, expectations and intentions; and other statements including words such as “anticipate”, “contemplate”, “continue”, “believe”, “plan”, “estimate”, “expect”, “intend”, “will”, “should”, “may”, and other similar expressions. Such statements constitute forward - looking statements within the meaning of securities laws. Although the Company believes that the views reflected in these forward - looking statements are reasonable, such statements involve significant risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making these forward - looking statements, and actual results may differ materially from those statements. Those factors and risks include, but are not limited to, our ability to raise the funds necessary to continue our operations, changing market conditions, the successful and timely completion of our clinical studies including delays, the demonstration of safety and efficacy of our drug candidates, our ability to recruit patients, the establishment and maintenance of corporate alliances, the market potential of our product candidates, the impact of competitive products and pricing, new product development, changes in laws and regulations, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly filings and annual reports. Forward - looking statements contained in this document represent views only as of the date hereof and are presented for the purpose of assisting potential investors in understanding the Company’s business, and may not be appropriate for other purposes. The Company does not undertake to update any forward - looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors should read the Company’s continuous disclosure documents available at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml , especially the risk factors detailed therein.
Aptose Biosciences (NASDAQ: APTO) 3 Building a pipeline of “Best in Class” targeted therapies to serve cancer patients with hematologic malignancies • Precision therapeutics designed to provide single agent efficacy and to be used in combination with conventional anti - cancer therapies and other targeted therapies • Targeting key drivers of disease in cancer cells without overlapping toxicities to provide efficacy with safety to improve the quality of life for cancer patients Investor highlights • Experienced leadership team with deep expertise in kinase inhibitors & orphan hematologic diseases • Clinical stage oncology company with two highly differentiated myeloid kinase inhibitors HM43239 lead precision medicine as primary value driver o Safely achieved single agent efficacy o Multiple complete responses (CR); response rates up to 40%+ o Profile supports single agent accelerated path ; clinical development progressing to combination therapy o Positioned to become a preferred agent for broad commercial use • Value - driving clinical updates and milestones through 2022 and 2023 • Value potential: Market Cap. $75M, $294M June 2021; 52 - Week range: high $3.13, low $0.73
Aptose Biosciences: Clinical Stage Pipeline of Differentiated Myeloid Kinase Inhibitors 4 LUXEPTINIB (CG - 806) dual lymphoid and myeloid kinase inhibitor High Value Targets Activity in Ill Patients Improved Formulation | B - cell cancers, AML/MDS and inflammation: BTK, FLT3, LCK, LYN, Others | Difficult to treat R/R B - cell lymphoma/CLL and R/R AML patients | G3 formulation being explored to reduce drug substance and increase plasma exposure HM43239 oral myeloid kinase inhibitor clinically validated for R/R AML patients Clinically Safe & Effective | 25 - 44% ORR in Phase 1/2 Trial with CRs in diverse & difficult to treat R/R AML patients Near - term Value Creation | Expansion Trials begin 2022 as passage into Registrational Studies planned for 2023 Orphan and Fast Track | Designations earned with impressive clinical responses across AML populations Broad Market Opportunities | Across R/R and front line, fit and unfit, induction and maintenance therapies
Aptose Leadership Team : Multifaceted Expertise in Therapeutic Development William G. Rice, PhD Chairman, President & Chief Executive Officer Philippe Ledru Sr. VP & Chief Commercial Officer Rafael Bejar, MD, PhD Sr. VP & Chief Medical Officer Fletcher Payne Sr. VP & Chief Financial Officer 5
Aptose SAB : Distinguished Opinion Leaders with Deep Oncology Expertise 6 Brian J. Druker, MD Pioneer in the field of precision medicine Key Role in development of Gleevec - the first targeted kinase inhibitor for cancer Member, National Academy of Medicine, National Academy of Sciences & American Academy of Arts & Sciences Winner of Karnofsky Award, Lasker Award, Japan Prize in Healthcare and Medical Technology, Tang Prize in Biopharmaceutical Science, Sjöberg Prize Leader of Inter - institutional Beat AML Initiative Michael Andreeff, MD, PhD Renowned hematology specialist Professor of Medicine Paul and Mary Haas Chair in Genetics Chief, Section of Molecular Hematology and Therapy MD Anderson Cancer Center Expert in AML and other hematologic malignancies Expert in drug resistance and drug mechanisms Daniel Von Hoff, MD, FACP Former President of AACR Board Member of ASCO Former Presidential Cancer Advisory Board Physician in Chief, TGen Medical Director of Research for McKesson Specialty Health Chief Scientific Officer for US Oncology Research Professor of Medicine, Mayo Clinic Scottsdale
7 HM43239 “239” Ora l , Da i l y, Mye l o i d K i na se I nhi b i tor
AML in the US : Estimated 20,240 new cases and 11,400 deaths in 2021 Continued Unmet Need for More Effective and Safe Therapies 8 Epidemiology US (2021) EU5 (2020) Japan (2021) China (2020) Leukemia Incidence 3 61,090 1 51,820 3 14,600 7 85,400 AML Incidence 20,240 2 16,580 3a 6,570 7c 31,430 3b 5 - Year Prevalence(Leukemia) (2020) 3 187,560 152,230 41,280 241,750 Mortality (Leukemia) 11,400 (AML) 2 31,690 8,700 7 61,690 a EU 5 incidence calculated by applying 32 % (AML) on leukemia to obtain incidence of AML 6 b In China, AML accounted for ~ 36 . 8 % of all leukemias 5 c In Japan, AML accounted for ~ 45 % of all leukemias in 2008 4 Sources: 1. SEER_2021 Leukemia ; 2. SEER 2021 AML ; 3. The Global Cancer Observatory (GLOBOCAN) - IACR (2020) - Projections ; 4. Chihara et al. Br J Haematol. 2014 ; 5. Chen et al. J Hematol Oncol. 2010: 21 ; 6. Cancer.net ; 7. Ganjoho Cancer Statistics in Japan 2021 *https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC7486485/ *https:// www.frontiersin.org/articles/10.3389/fonc.2021.649209/full Deadly and heterogeneous cancer with 5 - year survival rate at diagnosis of approx. 29% Relapsed AML patients have a median life expectancy of < 6 months * with approved therapies Need more effective & better tolerated targeted agents ─ DURABILITY to achieve lasting remissions and extend meaningful/quality life ─ SAFETY for maintenance / MRD+ therapy and for drug combination therapy ─ BREADTH to better treat R/R AML patients and overcome resistance to current agents Safe and effective agents expected to expand AML market and command significant market share
HM43239 Effective and Well Tolerated Targeted Agent Proven Broad Clinical Activity in AML Patients to Treat Significant Unmet Needs HM43239 AML Kinase Inhibitor Single Agent CRs CR and No DLT at 3 dose levels Broad Therapeutic Window No drug - related SAE, QTc toxicities, or CK increases Validated AML Targets SYK, FLT3 WT/MUT , JAK1/2, cKIT MUT Accelerated Paths to Market in R/R Disease ORR 43% in FLT3 MUT R/R AML CRs in patients failed prior FLT3i ORR 25% in TP53 MUT R/R AML Harboring adverse mutations Broad Market Potential R/R, 1L, Maintenance/MRD+/Combination 9
Emerging Clinical Data Support HM43239 as Potential Superior Therapy 10
HM43239 Phase 1/2 Study in R/R AML: Ongoing Dose Escalation & Dose Exploration 11 PART A : DOSE ESCALATION PART B : DOSE EXPLORATION Cohort 6 200 mg QD Ongoing Cohort 5 160 mg QD Completed Cohort 4 120 mg QD Completed Cohort 3 80 mg QD Completed Cohort 2 40 mg QD Completed Cohort 1 20 mg QD Completed 160 mg QD 9 Treated → 20 Planned 80 mg QD 20 Treated 120 mg QD Dose Exploration continues across several cohorts: currently enrolling patients at 120 mg and 160 mg dose levels and plan to explore 40 mg dose level Favorable safety profile: No drug related SAE or death and no observed relation between delta - QTc throughout the trial. And no DLT through 160 mg dose level. CRc 12 Treated → 20 Planned CRc CRc DLT DLT DLT Data as of July 14, 2022
HM43239 Safety and Efficacy Data Revealed a Broad Therapeutic Window as a Single Agent in R/R AML Patients 12 CONFIDETIAL • Safety Profile Favorable to Date ― No drug related SAE, deaths, or AE of elevated CK (creatine kinase) ― No drug related AE of QT prolongation – No observed relation between QTc and dose ― No DLT up to 160 mg and one DLT of muscle weakness (not rhabdomyolysis) at 200 mg • Demonstrated Efficacy Across a Diverse Set of R/R AML Patients — CRc in AML with Adverse Mutations (FLT3 WT ) incl. TP53 - Mutant and Complex Karyotype) — CRc in FLT3 - Mutant AML (Fast Track) incl. Prior Failure of Other FLT3 Inhibitors • Identified a Broad Therapeutic Window ― Safely achieved efficacy at 3 separate dose levels (80 mg, 120 mg, 160 mg) with no DLT ― Demonstrated broad therapeutic range across safe dose levels ― Safety profile supports combination therapy with other agents Data as of July 14, 2022
HM43239 Diversity of R/R AML Patients Who Achieved a Clinical Response to Date in Phase 1/2 Study Abbreviation: CR, complete response; CRi, complete response with incomplete hematologic recovery; CRp, complete response with incomplete platelet recovery; HSCT, hematopoietic stem cell transplantation; NE, not evaluable; PD, progressive disease; PR, partial remission. Note: 'Ongoing' means treatment is still ongoing; 'Remain Alive' indicates patients’ status in follow - up after treatment termination; The right arrow at the end of horizontal bar indicates patients are still on study, whereas without the right arrow indicates patients discontinued from study. Note: Each response assessed at a regular visit is considered to have started 1 cycle before the assessment; however the start of the response is considered the integer part of (study day/28) if the response occurred at the End of Treatment visit. * Indicates patients who received prior FLT3 inhibitors, including gilteritinib and/or midostaurin. Data as of July 14, 2022 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Duration of Treatment in Cycle S2601 S1408 S2220 S2203 S2211 S2212 S2216 Patient ID Death * * * WT ITD ITD WT FLT3 mutation 160 mg 120 mg 120 mg 80 mg 80 mg 80 mg 80 mg 80 mg Treatment CR NE HSCT/Remain Alive PR Refractory Remain Alive CRi CRp CR PD Remain Alive CRi HSCT/Remain Alive Refractory CRi CR HSCT/Remain Alive CRi CR CRi HSCT/Remain Alive CRi PD HSCT/Remain Alive CRp Ongoing NRAS RUNX1 KRAS NPM1 DNMT3A PTPN11 TP53 IDH2 SRSF2 MLL - PTD RUNX1 NPM1 DNMT3A RUNX1 SF3B1 RB1 Important Mutations TKD * S1301 ITD * ITD * WT 13 NRAS BCOR U2AF1 SETBP1
HM43239 AML Patients with Best Clinical Responses to Date Observed 7 CRc and 1 PR in Diverse and Challenging Patient Populations 14 R/R AML FLT3 Mutated FLT3 - ITD FLT3 - ITD FLT3 - ITD Prior Mido/Gilt FLT3 - WT Normal Cytogenetics Abnormal Cytogenetics Abnormal Cytogenetics NRAS RUNX1 KRAS NPM1 DNMT3A PTPN11 TP53 IDH2, SRSF2 CR i 80mg HSCT CR CRi 80mg 160mg HSCT CR 80mg HSCT CRi 120mg HSCT PR 120mg 4 Cycles FLT3 - ITD Prior Mido MLL - PTD RUNX1 CR 80mg 14 Cycles FLT3 Un - mutated FLT3 - WT FLT3 - WT NPM1 DNMT3A FLT3 - D835V Prior Mido/Gilt RUNX1, SF3B1, RB1 CR 80mg HSCT Normal Cytogenetics Normal Cytogenetics Normal Cytogenetics Normal Cytogenetics Normal Cytogenetics NRAS BCOR U 2 AF 1 SETBP 1 Data as of July 14, 2022
Abbreviation: CR, complete remission; CRc, composite complete remission; CRp, complete remission with incomplete platelet recovery; CRi, complete remission with incomplete hematological recovery; PR, partial remission. Note: efficacy evaluable patients include all patients with at least 80% drug compliance during Cycle 1 or who had reported a DLT during Cycle 1, and who reported relevant data for efficacy interpretation such as bone marrow assessment, CBC counts, reason for treatment termination. [1] Overall response includes CRc and PR. [2] CRc includes CR, CRh, CRp and CRi. [3] The reported prior FLT3 inhibitors include gilteritinib, midostaurin and soranfenib. Data as of July 14, 2022 HM43239 Overall Response Rate (CRc + PR) 7 CRc and 1 PR to Date in Phase 1 as a Single Agent in R/R AML Patients 15 Mutation Status All Patients Evaluable Patients N = 45 Patients Number Responder s Response Rate N = 41 Patients Number Responders Response Rate FLT3+ 20 5 25% 19 5 26.3% FLT3+ with prior FLT3i 7 3 42.9% 7 3 42.9% FLT3 - WT 25 3 12% 22 3 13.6% TP53+ 4 1 25% 3 1 33.3% Overall Response Rate for ”All Patients” and “Evaluable Patients” Receiving ≥ 80mg HM43239 — Findings represent a snapshot in time: The reported safety, tolerability, PK, PD and efficacy findings reported herein represent the data available may change as additional patients are assessed and more data are collected. — “Evaluable Patients” removes those non - evaluable patients who did not have a response evaluation and had no other evidence indicating refractory disease in the peripheral blood. — Most CRc patients went to HSCT and cannot be evaluated for transfusion independence assessment.
HM43239 Potential for Accelerated Path Supported by Expansion & Registration Trials 16 Current Dose Escalation/Dose Exploration Phase 1/2 Trial in R/R AML Patients — Continue Exploration of Molecular Subgroups (Genotypes) for Potential Fast Track Designations o Expect Continued Dose Exploration at 120 mg and 160 mg to Deliver Rolling News Flow — Selected 3 Expansion Doses (80 mg, 120 mg, 160 mg) and Patient Populations for Expansion Trials Transitioning to Expansion Trials in AML Patients as Run - up to Registrational Trials — 120 mg planned as Primary Single Agent Expansion Dose with 80 mg and 160 mg as Bracketing Doses — FLT3 Mutated R/R AML Expansions ( Fast Track Designation ), including Prior FLT3i Failure o Plan Single Agent to begin 2H2022 and Combination (239+Ven) to begin 1H2023 — FLT3 - Unmutated R/R AML Expansions (with Adverse Mutations), including TP53 - Mutated o Plan Single Agent to begin 2H2022 and Combination (239+Ven) to begin 1H2023 — Registrational Trial(s) planned to begin 2H2023 via segue from Expansions
HM43239 Single Agent FLT3 - Mutated Cohort: ─ Prior FLT3i ─ FLT3i naïve FLT3 - Unmutated Cohort: ─ TP53 MUT /Complex Karyotype ─ Other HM43239 + Venetoclax Combo FLT3 - Mutated Cohort FLT3 - Unmutated Cohort HM43239 Global Dose Expansion Trial Planned to Support Phase 2 Registrational Trials for Accelerated Approval and Drug Combination Trials for Broad Commercialization Registrational Phase 2 study – Single Agent FLT3 MUT R/R AML with prior FLT3i therapy Combo Phase 2 Randomized Study R/R AML in 2L, FLT3 mutant – 239 vs. 239/VEN vs. GILT Registrational Phase 2 study – Single Agent TP53 MUT R/R AML, Complex Karyotype, or Other Group Combo Phase 2 - 3 Randomized Study 1L unfit AML: HMA/VEN vs. 239/HMA/VEN + maint 1L fit AML, FLT3 - WT: Chemo vs. 239/Chemo + maint Expansion Trials 2022 - 2023 Registrational Single Agent Trials Planned to Begin in 2023 if Data from Expansion Trial Support 12 - 16 patient data to justify Drug Combination Trial to Support Usage of 239 with Other Agents in AML Populations Accelerated Approval and Marketing • Single agent Expansion studies designed to collect data on a small number of patients in “high need” groups and segue into Ph 2 Registrational Trial(s) • Combination Expansion studies designed to illustrate safety and efficacy of 239 with venetoclax and segue into Phase 2 - 3 randomized studies and demonstrate 239 can be the preferred agent for combination therapy 17
Clinical Development Plan Sets the Stage for Broad Commercial Success 18
HM43239: Safely Delivers Clinical CRs in AML Patients with Diverse Mutations Broad Commercial Potential Unlike Any Other Targeted Agent for AML TP53 - Mutated AML IDH - Mutated AML RUNX1 - Mutated AML DNMT3A - Mutated AML FLT3 - Mutated AML RAS - Mutated AML NPM1 - Mutated AML MLL - Mutated AML HM43239 Myeloid Targets SYK JAK1/2 cKIT MUT FLT3 WT/MUT Suppression of a constellation of validated myeloid kinases by HM43239 safely delivers deep clinical responses in a broad array of AML genotypes Broad Commercial Potential 19
HM43239 TPP : Safe, Oral, Daily, Targeted Agent for Diverse AML Patients 20 Proven Broad Clinical Activity to Deliver Complete Remissions (CRs) in Diverse R/R AML Patients • Genetic diversity (FLT3, TP53, NRAS, KRAS, IDH1, IDH2, MLL, NPM1, PTPN11, DNMT3A, RUNX1, etc.) • FLT3 - unmutated (with complex karyotype and adverse mutations, incl. TP53 MUT ) • FLT3 - mutated (incl. prior failure by other FLT3i) • Three dose levels rendering CR with no DLT Developing as Single Agent (For Accelerated Approval) • FLT3 - Mutant R/R AML Failed Prior FLT3i | Fast Track Designation Awarded in FLT3 Mutated Patients • TP53 - Mutant AML / Complex Karyotype | Potential for Fast Track Designation if Data Continue to Support Developing in Combination with Venetoclax - /+ HMA • Global Phase 2 - 3 Randomized Drug Combination Trials in Earlier Lines of Therapy Efficacy with Strong Safety Profile Suggests Preferred Agent for Broad Commercial Usage • R/R Therapy in FLT3+/ - • Combination Therapy • 1L Therapy in Fit/Unfit and FLT3+/ - • Maintenance / MRD(+) Therapy
HM43239 Potential Commercial Opportunity in the AML Market AML Patient Population Segment Estimated Treatable Population with HM43239 Estimated Median Duration of Treatment Estimated Peak Market Share (%) US Sales Potential (2035) - USD FLT3(+) RR AML / Prior FLT3i (Gilt) ~ 400 3 months 60% ~$25 mil FLT3(+) RR AML / No Prior FLT3i ~ 1,500 3 months 50% ~$185 mil FLT3(WT) RR AML* ~ 1,500 7 months 60% ~$55 mil FLT3(+) 1L AML Unfit ~1,600 9 months 65% ~$160 mil FLT3(WT) 1L AML* Fit ~ 5,000 10 months 45% ~$420 mil FLT3(+/WT) Maintenance / MRD(+) ~5,000 Continuous 65% ~$450 mil 21 * Population with IDH1&2 - WT and either NPM1 and/or Chromatin mutations representing ~50% of the AML patient population. This segment excludes FLT3 and/or IDH1/2 mutant patients. Acute Myeloid Leukemia • The global AML market is experiencing strong growth and is predicted to grow to > $1.8 billion in 2026 Global Market Report 2022 • Effective and safe agents have the potential to expand the market further
Targets Constellation of Kinases Important in AML • Potent inhibitor of myeloid kinases SYK, FLT3 WT/MUT , JAK1/2 and mutant forms of c - KIT associated with transformation and resistance • Potential to treat genetically defined AML patients across multiple lines of therapy & populations • Safety & efficacy foretell significant market potential for R/R, 1L, FLT3 - /+, Fit/Unfit AML populations HM43239 Clinically Validated, Once Daily, Oral Myeloid Kinase Inhibitor Confidence of Clinical Investigators and KOLs Program Goals Supporting Rapid Development • Explore Molecular Subgroups for Potential Fast Track Designations • Single Agent Expansion Trial (239) planned 2H2022 • Combo Expansion Trial ( 239+Ven) planned 2H2022 • Registrational Ph2 study(ies) planned 2023 from Expansions • Broad commercialization goals supported by clinical development in diverse patient populations Clinical Validation Supports Path of Rapid Development for Breadth of AML Patients • FLT3 - Mutated Patients 22 — CRc in patients who failed prior FLT3 inhibitors (midostaurin and gilteritinib) — CRc in patients with ITD and TKD mutated FLT3 — FDA Fast Track received for FLT3 MUT R/R AML • FLT3 - Unmutated Patients — CRc in patients harboring diverse mutations : NPM 1 , DNMT 3 A, N/KRAS, MLL, TP 53 , IDH 2 , U 2 AF 1 , RUNX 1 , Others • Broad Therapeutic Window — Well tolerated across three active & safe doses • Preferred Agent Profile for Combination Therapy
HM43239 Potential Timelines of Value Driving Milestones Ph 1/2 Dose Escalation & Exploration Trial Sep Oct Nov Dec 2023 Jan Feb Mar Apr May Jun Jul Sep Oct Nov Dec EHA 2023 • Data Readout for SA & Combo Dose Expansion Trial ─ FLT3 - WT & FLT3+ ─ FLT3+ with prior FLT3i therapy ─ TP53 mutant patients • Announce plans for Registration Single Agent study • Announce plans for 1L triplet Phase I/II in unfit AML (all genotypes) • Describe post - CR maintenance study ASH 2023 • Data Readout for SA & Combo Dose Expansion Trial • Update Registrational Single Agent study in FT3 - mut with prior FLT3i • Report genomic associations with response/resistance • Announce plans for randomized Ph 2 239+Ven Combo study in R/R AML • Announce plans for follow - on front - line triplet randomized study ASH 2022 Data Readout for Dose Esc/Exp Dose Expansion Data Update ‒ SA/Combo & FLT3 - /+ Initiate SA & Combo Exp.Trial Initiate Registrational P2 Trial Ph 1/2 Dose Expansion Trial (FLT3 - /+ and SA/239+VenCombo) Ph 2 Registrational Trial Single Agent in FLT3+ with Prior FLT3i EOP1 Meeting 2022 Jul Aug Today EC EC Ph 2 Registrational Trial Single Agent in TP53 MUT EC EC Aug EC EC 23
Aptose Biosciences (NASDAQ: APTO) 24 Building a pipeline of “Best in Class” targeted therapies to serve cancer patients with hematologic malignancies • Precision therapeutics designed to provide single agent efficacy and to be used in combination with conventional anti - cancer therapies and other targeted therapies • Targeting key drivers of disease in cancer cells without overlapping toxicities to provide efficacy with safety to improve the quality of life for cancer patients Investor highlights • Experienced leadership team with deep expertise in kinase inhibitors & orphan hematologic diseases • Clinical stage oncology company with two highly differentiated myeloid kinase inhibitors HM43239 lead precision medicine as primary value driver o Safely achieved single agent efficacy o Multiple complete responses (CR); response rates up to 40%+ o Profile supports single agent accelerated path ; clinical development progressing to combination therapy o Positioned to become a preferred agent for broad commercial use • Value - driving clinical updates and milestones through 2022 and 2023 • Value potential: Market Cap. $75M, $294M June 2021; 52 - Week range: high $3.13, low $0.73
P R E C I S I O N O N C O L O G Y F O R T H E R A P I E S O F T O M O R R O W We thank our partners, investigators, and investors for helping us bring novel drugs to patients with the greatest need.